Celgene and Bristol-Myers Squibb have scored exits as the oncology drug developer priced an upsized offering above its range.
Silverback Therapeutics, a US-based immuno-oncology therapy developer backed by pharmaceutical firms Celgene and Bristol-Myers Squibb (BMS), went public today in an initial public offering sized at approximately $242m.
The company had upscaled the offering from 10 million shares to 11.5 million and priced them at $21.00 each, above a $19 to $20 range already increased from $17 to $19. It is floating on the Nasdaq Global Market and the IPO price values it at $695m.
Founded in 2016, Silverback…
